Developer docs
API playgroundTry for free, no card

Search company profiles

BioTelemetry

Full company profile

uuid000ow9q

Namestring
BioTelemetry
Legal namestring
BioTelemetry, Inc.
Websiteurl
gobio.com
Company typeenum
Public
Founded yearint
1994
Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersMalvern, United States
HQ citystring
Malvern
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
remote cardiac monitoring, mobile cardiac telemetry, ambulatory ECG diagnostics, wearable cardiac devices, remote patient monitoring
Industry4 codes
1Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders)
CodeHLAHACABPrimaryYes
2Connected Medical Devices & Wearables (Sensors, Patches, Implantables)
CodeHLACAPABPrimaryNo
3Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices)
CodeHLACAPAKPrimaryNo
4Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity)
CodeHLALAFAAPrimaryNo
NAICS code3 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Medical and Diagnostic Laboratories62151
  • Medical Laboratories621511
SIC code3 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
  • Services-Medical Laboratories8071
Product category
Remote Cardiac Diagnostics and Monitoring
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Remote Cardiac Monitoring Services
TypeSubscription Recurring
Description

Wearable heart monitors (MCOT patch, extended Holter) that detect and transmit abnormal heart rhythms wirelessly. Physician-prescribed monitoring services billed to insurance. Primary revenue driver representing 85% of sales.

gobio.com
2Centralized Core Laboratory Services
TypeProfessional Services
Description

Clinical research business providing testing services for clinical trials. Serves pharmaceutical and biotech companies conducting clinical research.

gobio.com
3Remote Blood Glucose Monitoring
TypeSubscription Recurring
Description

Remote patient monitoring platform for diabetes management. Includes On.Demand RPM platform acquired from Centene focusing on diabetes, hypertension, and chronic heart failure.

gobio.com
4Original Equipment Manufacturing
TypeHardware Sales
Description

OEM manufacturing services serving both healthcare and clinical research customers.

gobio.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain
Pricing details2 tiers
1Insurance-based service billing
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Services billed as flat rate per monitoring period, not based on number of days worn. Insurance providers billed; patient responsible for portion based on Explanation of Benefits.

gobio.com
2Remote INR Patient Self-Testing
ModelSubscriptionBilling cadenceMonthly
Notes

CoaguChek Vantus device for patient self-testing; training and support provided. Services include automated shipment of supplies, wireless result transmission.

gobio.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 7 records shown
1MCOT (Mobile Cardiac Outpatient Telemetry)
Description

Mobile cardiac telemetry system for arrhythmia detection with FDA approval, featuring SmartDetect algorithm and up to 30 days of monitoring.

gobio.com
+6 more records
Core offering1 text field

BioTelemetry delivers remote cardiac monitoring and diagnostics services through FDA-cleared wearable devices (MCOT patch and ePatch Extended Holter) that capture and transmit ECG data for AI-powered arrhythmia detection, supplemented by Remote INR self-testing for anticoagulation management, Geneva Healthcare's implantable device monitoring platform, and BioTel Research core lab services for clinical trials. Services are physician-prescribed, processed through centralized monitoring centers, and delivered into major EMR systems for healthcare providers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • MCOT detected AF in 23% of cryptogenic stroke patients (single center study)
+4 more records
Product overview1 text field

BioTelemetry, a Philips company operating as Philips Ambulatory Monitoring and Diagnostics, offers a unified portfolio of remote cardiac diagnostics, monitoring, and patient management solutions. The core product suite is anchored by MCOT (Mobile Cardiac Outpatient Telemetry) — a flagship AI-powered wearable cardiac telemetry patch — and ePatch (Extended Holter) — a 3–14 day continuous ECG recording device. These are complemented by Remote INR for INR self-testing, a suite of Clinical Pathways (stroke, ED discharge, primary care, AF ablation, TAVR) that integrate MCOT and ePatch into specific care workflows, and an EMR Integration module that delivers reports directly into EPIC, Cerner, Allscripts, and other hospital systems. BioTelemetry also operates Geneva Healthcare (implantable device data management), BioTel Research (centralized core lab services for clinical trials), and manages the On.Demand chronic RPM platform for diabetes, hypertension, and heart failure coaching. Following Philips' USD 2.8 billion acquisition in February 2021, the portfolio is consolidated under the Philips Ambulatory Monitoring and Diagnostics brand while preserving the BioTelemetry, BioTel Heart, CardioNet, and Geneva Healthcare sub-brands.

Product and service8 records
1MCOT (Mobile Cardiac Outpatient Telemetry)
CategoryRemote Cardiac Monitoring Service
Description

MCOT is BioTelemetry's flagship mobile cardiac telemetry system for continuous arrhythmia detection and monitoring. Patients wear a small, lightweight, water-resistant patch that captures two channels of ECG data for up to 30 days. The SmartDetect AI algorithm processes data in real time and delivers urgent/emergent, daily, and end-of-service reports reviewed by cardiac technicians, enabling rapid diagnosis of atrial fibrillation and other arrhythmias.

2ePatch (Extended Holter)
CategoryRemote Cardiac Monitoring Service
Description

ePatch is Philips' extended Holter monitoring solution providing 3-14 days of continuous ECG recording with 99% patient compliance. Powered by Philips' medical-grade AI, it delivers actionable reports within 24 hours of upload, supporting arrhythmia detection, AF burden quantification, and ectopic beat analysis. Features flexible wear options (patch, FLEX electrode, lead wire) and EMR integration.

3Remote INR Patient Self-Testing
CategoryRemote Patient Monitoring Service
Description

Remote INR is BioTelemetry's INR (International Normalized Ratio) patient self-testing platform enabling warfarin patients to test their blood clotting levels at home using a CoaguChek Vantus device. Results are transmitted via a mobile app (Bluetooth), online portal, or automated phone system, with healthcare providers receiving real-time reports to adjust medication dosing. The service supports patient self-testing enrollment, compliance tracking, and 24/7 support.

4Geneva Healthcare Platform
CategoryImplantable Device Monitoring Platform
Description

Cloud-based vendor-neutral remote monitoring platform for implantable cardiac device data management acquired by BioTelemetry in March 2019. Integrates with scheduling and DFT (Device Follow-Up) tracking for managing pacemaker and defibrillator patients. Protected by U.S. Patent Nos. 10,679,739 and D763879.

5On.Demand Remote Patient Monitoring Platform
CategoryChronic Remote Patient Monitoring Service
Description

On.Demand is a chronic RPM and coaching platform acquired by BioTelemetry from Centene subsidiary Envolve People Care in July 2020. The platform provides chronic RPM and coaching for diabetes, hypertension, and chronic heart failure, combining real-time biometric monitoring with cellular- and web-based technology, proactive/reactive health coaching, population health reporting, and customizable interventions including Alexa Skill integration.

6LUX-Dx Insertable Cardiac Monitor (ICM) (Sales Agent)
CategoryImplantable Cardiac Device Distribution
Description

BioTelemetry serves as a sales agent in the United States for the Boston Scientific LUX-Dx Insertable Cardiac Monitor (ICM) System, the first ICM device with remote programming capability and a dual-stage arrhythmia detection algorithm. This adds an implantable cardiac monitor option to BioTelemetry's device portfolio of Holter, Extended Holter, Event monitors, and MCOT.

7BioTel Research (Centralized Core Laboratory)
CategoryClinical Research Centralized Core Lab Services
Description

BioTelemetry's centralized core laboratory services for clinical trials, providing testing services for pharmaceutical and medical device clinical research. Supported by proprietary patents (U.S. Patent Nos. 6,731,782; 6,801,646; 6,836,557; 6,950,544; 7,103,224; 7,233,687; 7,346,201; 7,406,211; 6,664,893; 7,002,468; 8,425,414; 9,474,445).

8BioTel Heart (Unified Cardiac Monitoring Services)
CategoryRemote Cardiac Monitoring Service Suite
Description

Consolidated service brand (launched in 2018) combining BioTelemetry's remote cardiac monitoring services including MCOT, ePatch, event monitors, Holter, and implantable device monitoring under the unified BioTel Heart brand, now integrated into Philips Ambulatory Monitoring and Diagnostics.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2020-07-30
Description

Sales agent agreement for LUX-Dx Insertable Cardiac Monitor (ICM) System. BioTelemetry became sales agent in the US for the first ICM device with remote programming and dual-stage arrhythmia detection algorithm. Expands device portfolio beyond Holter, Extended Holter, Event monitors, and MCOT.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-07-29
Description

Acquisition of On.Demand remote patient monitoring platform from Centene subsidiary Envolve People Care. BioTelemetry became exclusive provider of diabetes RPM services to Centene Medicaid members. Platform adds chronic RPM and coaching for diabetes, hypertension, and chronic heart failure.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2020-01-01
Description

BioTelemetry assumed responsibility to service Roche's remote INR patient base, expanding their Remote INR monitoring services.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Joint recipient of 2017 IoT Evolution Business Impact Award for IoT impact in healthcare remote monitoring.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Non-profit partnership providing life-saving surgeries and medical care for children with heart disease in Southeast Asia. Heart for Hope program has completed over 740 heart surgeries.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Vietnam hospital partnership for outreach program connecting patients to Heart for Hope program for congenital heart disease treatment.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

2013 partnership to develop next generation cardiac monitoring products.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

iRhythm's Zio suite is a direct competitor in ambulatory cardiac monitoring, offering extended-wear patch Holter and MCT services to cardiology and primary care accounts. Both companies compete on diagnostic yield, wear time, AI-powered reporting, and EMR-integrated workflows for arrhythmia detection.

TypeDirect peer
Description

AliveCor's KardiaMobile ECG devices and KardiaCloud platform provide patient- and provider-facing single-lead ECG and remote cardiac monitoring. It directly overlaps with BioTelemetry's primary care screening and arrhythmia detection use cases, especially at the lower-acuity end of the ambulatory ECG market.

TypeBroad incumbent
Description

Boston Scientific is both a channel partner (LUX-Dx ICM sales agent agreement) and a broader incumbent in cardiac diagnostics and implantable cardiac devices. Its ICM and electrophysiology portfolio competes with Geneva's implantable device platform while its CRM franchise competes more broadly in cardiac care.

TypeBroad incumbent
Description

Medtronic's Cardiac Rhythm Management franchise competes in implantable cardiac monitors (Reveal LINQ), diagnostics, and remote monitoring services through its CareLink network. It is a broad incumbent with overlapping implantable and ambulatory cardiac monitoring capabilities.

TypeEmerging player
Description

HeartBeam is an emerging player developing a credit-card-sized 3D vector ECG platform for at-home and ambulatory cardiac diagnostics. Its technology focuses on synthesizing a 12-lead equivalent from a portable device — adjacent to BioTelemetry's ambulatory ECG franchise.

TypeEmerging player
Description

InfoBionic offers a cloud-based remote cardiac telemetry platform (MoMe ARC) for ambulatory arrhythmia monitoring and reporting. As an emerging niche player, it competes with BioTelemetry's MCOT and ePatch services on AI-driven arrhythmia detection workflows.

TypeOthers
Description

Hillrom (now part of Baxter) and its Welch Allyn franchise provide adjacent ambulatory and primary care diagnostic devices used in cardiology workflows. They serve as an ecosystem/adjacent player rather than a direct ambulatory cardiac monitoring competitor.

TypeBroad incumbent
Description

GE Healthcare's Muse is one of the dominant in-hospital ECG management systems and an integration partner for BioTelemetry. As a broader incumbent in diagnostic cardiology, it competes across inpatient and adjacent ambulatory ECG workflows.

TypeBroad incumbent
Description

Royal Philips is the parent company of BioTelemetry following the 2021 acquisition. Philips' broader Connected Care and Diagnostic Imaging businesses (IntelliSpace ECG, patient monitoring) provide the in-hospital counterpart to BioTelemetry's outpatient cardiac monitoring portfolio.

TypeBroad incumbent
Description

Abbott's cardiovascular portfolio includes insertable cardiac monitors (Confirm Rx), diagnostics, and remote monitoring. It is a broad incumbent in cardiac care whose implantable and ambulatory monitoring assets overlap with BioTelemetry's franchise.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration11 records

Each record includes

Title, Type, Description, Source

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries15 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioTelemetry

Remote Cardiac Diagnostics and Monitoringgobio.com

BioTelemetry firmographics

Firmographics
Name
BioTelemetry
Legal name
BioTelemetry, Inc.
Website
https://gobio.com
Company type
Public
Founded year
1994
Operating status
Acquired
Headcount range
1,001–5,000 employees
Ownership category
akta.pro rank

BioTelemetry industry classification

Industry
Product category
Remote Cardiac Diagnostics and Monitoring
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845), Services-Medical Laboratories (8071)
akta.pro primary industry
Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders) (HLAHACAB)
akta.pro secondary industries
Connected Medical Devices & Wearables (Sensors, Patches, Implantables) (HLACAPAB), Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK), Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA)

Keywords

  • Remote cardiac monitoring
  • Mobile cardiac telemetry
  • Ambulatory ECG diagnostics
  • Wearable cardiac devices
  • Remote patient monitoring

Where BioTelemetry is headquartered

Location

Headquarters

HQ city
Malvern
HQ country
United States
HQ region
North America

Offices2 records

Markets served

BioTelemetry business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Remote Cardiac Monitoring Services: Wearable heart monitors (MCOT patch, extended Holter) that detect and transmit abnormal heart rhythms wirelessly. Physician-prescribed monitoring services billed to insurance. Primary revenue driver representing 85% of sales.
  2. Centralized Core Laboratory Services: Clinical research business providing testing services for clinical trials. Serves pharmaceutical and biotech companies conducting clinical research.
  3. Remote Blood Glucose Monitoring: Remote patient monitoring platform for diabetes management. Includes On.Demand RPM platform acquired from Centene focusing on diabetes, hypertension, and chronic heart failure.
  4. Original Equipment Manufacturing: OEM manufacturing services serving both healthcare and clinical research customers.

Pricing tiers

ModelBillingPrice
SubscriptionMulti-year contractInsurance-based service billing
SubscriptionMonthlyRemote INR Patient Self-Testing

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

BioTelemetry product offering

Product offering

Core offering

BioTelemetry delivers remote cardiac monitoring and diagnostics services through FDA-cleared wearable devices (MCOT patch and ePatch Extended Holter) that capture and transmit ECG data for AI-powered arrhythmia detection, supplemented by Remote INR self-testing for anticoagulation management, Geneva Healthcare's implantable device monitoring platform, and BioTel Research core lab services for clinical trials. Services are physician-prescribed, processed through centralized monitoring centers, and delivered into major EMR systems for healthcare providers.

Product overview

BioTelemetry, a Philips company operating as Philips Ambulatory Monitoring and Diagnostics, offers a unified portfolio of remote cardiac diagnostics, monitoring, and patient management solutions. The core product suite is anchored by MCOT (Mobile Cardiac Outpatient Telemetry) — a flagship AI-powered wearable cardiac telemetry patch — and ePatch (Extended Holter) — a 3–14 day continuous ECG recording device. These are complemented by Remote INR for INR self-testing, a suite of Clinical Pathways (stroke, ED discharge, primary care, AF ablation, TAVR) that integrate MCOT and ePatch into specific care workflows, and an EMR Integration module that delivers reports directly into EPIC, Cerner, Allscripts, and other hospital systems. BioTelemetry also operates Geneva Healthcare (implantable device data management), BioTel Research (centralized core lab services for clinical trials), and manages the On.Demand chronic RPM platform for diabetes, hypertension, and heart failure coaching. Following Philips' USD 2.8 billion acquisition in February 2021, the portfolio is consolidated under the Philips Ambulatory Monitoring and Diagnostics brand while preserving the BioTelemetry, BioTel Heart, CardioNet, and Geneva Healthcare sub-brands.

Differentiator

Problem solved

Functional benefit

Brands

  • MCOT (Mobile Cardiac Outpatient Telemetry): Mobile cardiac telemetry system for arrhythmia detection with FDA approval, featuring SmartDetect algorithm and up to 30 days of monitoring.
  • ePatch
  • Remote INR
  • CardioKey
  • BioTel Research
  • Geneva Healthcare
  • On.Demand

Products and services

  • MCOT (Mobile Cardiac Outpatient Telemetry) MCOT is BioTelemetry's flagship mobile cardiac telemetry system for continuous arrhythmia detection and monitoring. Patients wear a small, lightweight, water-resistant patch that captures two channels of ECG data for up to 30 days. The SmartDetect AI algorithm processes data in real time and delivers urgent/emergent, daily, and end-of-service reports reviewed by cardiac technicians, enabling rapid diagnosis of atrial fibrillation and other arrhythmias.
  • ePatch (Extended Holter) ePatch is Philips' extended Holter monitoring solution providing 3-14 days of continuous ECG recording with 99% patient compliance. Powered by Philips' medical-grade AI, it delivers actionable reports within 24 hours of upload, supporting arrhythmia detection, AF burden quantification, and ectopic beat analysis. Features flexible wear options (patch, FLEX electrode, lead wire) and EMR integration.
  • Remote INR Patient Self-Testing Remote INR is BioTelemetry's INR (International Normalized Ratio) patient self-testing platform enabling warfarin patients to test their blood clotting levels at home using a CoaguChek Vantus device. Results are transmitted via a mobile app (Bluetooth), online portal, or automated phone system, with healthcare providers receiving real-time reports to adjust medication dosing. The service supports patient self-testing enrollment, compliance tracking, and 24/7 support.
  • Geneva Healthcare Platform Cloud-based vendor-neutral remote monitoring platform for implantable cardiac device data management acquired by BioTelemetry in March 2019. Integrates with scheduling and DFT (Device Follow-Up) tracking for managing pacemaker and defibrillator patients. Protected by U.S. Patent Nos. 10,679,739 and D763879.
  • On.Demand Remote Patient Monitoring Platform On.Demand is a chronic RPM and coaching platform acquired by BioTelemetry from Centene subsidiary Envolve People Care in July 2020. The platform provides chronic RPM and coaching for diabetes, hypertension, and chronic heart failure, combining real-time biometric monitoring with cellular- and web-based technology, proactive/reactive health coaching, population health reporting, and customizable interventions including Alexa Skill integration.
  • LUX-Dx Insertable Cardiac Monitor (ICM) (Sales Agent) BioTelemetry serves as a sales agent in the United States for the Boston Scientific LUX-Dx Insertable Cardiac Monitor (ICM) System, the first ICM device with remote programming capability and a dual-stage arrhythmia detection algorithm. This adds an implantable cardiac monitor option to BioTelemetry's device portfolio of Holter, Extended Holter, Event monitors, and MCOT.
  • BioTel Research (Centralized Core Laboratory) BioTelemetry's centralized core laboratory services for clinical trials, providing testing services for pharmaceutical and medical device clinical research. Supported by proprietary patents (U.S. Patent Nos. 6,731,782; 6,801,646; 6,836,557; 6,950,544; 7,103,224; 7,233,687; 7,346,201; 7,406,211; 6,664,893; 7,002,468; 8,425,414; 9,474,445).
  • BioTel Heart (Unified Cardiac Monitoring Services) Consolidated service brand (launched in 2018) combining BioTelemetry's remote cardiac monitoring services including MCOT, ePatch, event monitors, Holter, and implantable device monitoring under the unified BioTel Heart brand, now integrated into Philips Ambulatory Monitoring and Diagnostics.

Quantifiable outcome

  • MCOT detected AF in 23% of cryptogenic stroke patients (single center study)
  • +4 more outcomes

Companies that use BioTelemetry

Customer profile

Named customers3 records

Segments5 records

Ideal customer profiles4 records

BioTelemetry technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration11 records

AI capability7 records

Feature5 records

BioTelemetry partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • Boston ScientificcoreChannel Partner/ Reseller/ Distributor · 30 July 2020Sales agent agreement for LUX-Dx Insertable Cardiac Monitor (ICM) System. BioTelemetry became sales agent in the US for the first ICM device with remote programming and dual-stage arrhythmia detection algorithm. Expands device portfolio beyond Holter, Extended Holter, Event monitors, and MCOT.
  • Centene CorporationcoreStrategic or Co-development Partner · 29 July 2020Acquisition of On.Demand remote patient monitoring platform from Centene subsidiary Envolve People Care. BioTelemetry became exclusive provider of diabetes RPM services to Centene Medicaid members. Platform adds chronic RPM and coaching for diabetes, hypertension, and chronic heart failure.
  • RochecoreChannel Partner/ Reseller/ Distributor · 1 January 2020BioTelemetry assumed responsibility to service Roche's remote INR patient base, expanding their Remote INR monitoring services.
  • SprintminorStrategic or Co-development Partner · 1 January 2020Joint recipient of 2017 IoT Evolution Business Impact Award for IoT impact in healthcare remote monitoring.
  • Giving it Back to KidsminorStrategic or Co-development PartnerNon-profit partnership providing life-saving surgeries and medical care for children with heart disease in Southeast Asia. Heart for Hope program has completed over 740 heart surgeries.
  • Hoan My HospitalminorStrategic or Co-development PartnerVietnam hospital partnership for outreach program connecting patients to Heart for Hope program for congenital heart disease treatment.
  • IMEC and DeltaminorStrategic or Co-development Partner2013 partnership to develop next generation cardiac monitoring products.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

BioTelemetry competitors and assessment

Company assessment

Direct peers

  • iRhythm Technologies: iRhythm's Zio suite is a direct competitor in ambulatory cardiac monitoring, offering extended-wear patch Holter and MCT services to cardiology and primary care accounts. Both companies compete on diagnostic yield, wear time, AI-powered reporting, and EMR-integrated workflows for arrhythmia detection.
  • AliveCor: AliveCor's KardiaMobile ECG devices and KardiaCloud platform provide patient- and provider-facing single-lead ECG and remote cardiac monitoring. It directly overlaps with BioTelemetry's primary care screening and arrhythmia detection use cases, especially at the lower-acuity end of the ambulatory ECG market.

Broad incumbents

  • Boston Scientific: Boston Scientific is both a channel partner (LUX-Dx ICM sales agent agreement) and a broader incumbent in cardiac diagnostics and implantable cardiac devices. Its ICM and electrophysiology portfolio competes with Geneva's implantable device platform while its CRM franchise competes more broadly in cardiac care.
  • Medtronic: Medtronic's Cardiac Rhythm Management franchise competes in implantable cardiac monitors (Reveal LINQ), diagnostics, and remote monitoring services through its CareLink network. It is a broad incumbent with overlapping implantable and ambulatory cardiac monitoring capabilities.
  • GE Healthcare (incl. Muse): GE Healthcare's Muse is one of the dominant in-hospital ECG management systems and an integration partner for BioTelemetry. As a broader incumbent in diagnostic cardiology, it competes across inpatient and adjacent ambulatory ECG workflows.
  • Koninklijke Philips (Royal Philips): Royal Philips is the parent company of BioTelemetry following the 2021 acquisition. Philips' broader Connected Care and Diagnostic Imaging businesses (IntelliSpace ECG, patient monitoring) provide the in-hospital counterpart to BioTelemetry's outpatient cardiac monitoring portfolio.
  • Abbott: Abbott's cardiovascular portfolio includes insertable cardiac monitors (Confirm Rx), diagnostics, and remote monitoring. It is a broad incumbent in cardiac care whose implantable and ambulatory monitoring assets overlap with BioTelemetry's franchise.

Emerging players

  • HeartBeam: HeartBeam is an emerging player developing a credit-card-sized 3D vector ECG platform for at-home and ambulatory cardiac diagnostics. Its technology focuses on synthesizing a 12-lead equivalent from a portable device — adjacent to BioTelemetry's ambulatory ECG franchise.
  • InfoBionic: InfoBionic offers a cloud-based remote cardiac telemetry platform (MoMe ARC) for ambulatory arrhythmia monitoring and reporting. As an emerging niche player, it competes with BioTelemetry's MCOT and ePatch services on AI-driven arrhythmia detection workflows.

Others

  • Hillrom (Baxter) / Welch Allyn: Hillrom (now part of Baxter) and its Welch Allyn franchise provide adjacent ambulatory and primary care diagnostic devices used in cardiology workflows. They serve as an ecosystem/adjacent player rather than a direct ambulatory cardiac monitoring competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

BioTelemetry social profiles

Digital presence

BioTelemetry compliance and trust

Trust signal

Compliance2 records

BioTelemetry financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioTelemetry leadership team

Management profile

Number of profiles

Profiles7 records

BioTelemetry subsidiaries and ownership

Company hierarchy

Subsidiaries15 records

BioTelemetry funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioTelemetry M&A and investment

M&A and investment

M&A4 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioTelemetry

What does BioTelemetry do?

BioTelemetry delivers remote cardiac monitoring and diagnostics services through FDA-cleared wearable devices (MCOT patch and ePatch Extended Holter) that capture and transmit ECG data for AI-powered arrhythmia detection, supplemented by Remote INR self-testing for anticoagulation management, Geneva Healthcare's implantable device monitoring platform, and BioTel Research core lab services for clinical trials. Services are physician-prescribed, processed through centralized monitoring centers, and delivered into major EMR systems for healthcare providers.

Is BioTelemetry a public or private company?

BioTelemetry is a public company. It is classified as corporate owned and is currently acquired.

When was BioTelemetry founded?

BioTelemetry was founded in 1994. It employs 1,001 to 5,000 people.

Where is BioTelemetry based?

BioTelemetry is headquartered in Malvern, United States, in the North America region.

How does BioTelemetry make money?

Four revenue lines are on record. Remote Cardiac Monitoring Services are the primary driver. The others are centralized Core Laboratory Services, remote Blood Glucose Monitoring and original Equipment Manufacturing.

Who are BioTelemetry's main competitors?

Direct peers on record are iRhythm Technologies and AliveCor. Broad incumbents are Boston Scientific, Medtronic, GE Healthcare (incl. Muse), Koninklijke Philips (Royal Philips) and Abbott. Emerging players are HeartBeam and InfoBionic. Hillrom (Baxter) / Welch Allyn is listed as an others.

Does BioTelemetry have an API?

No public API is recorded for BioTelemetry.

What industry is BioTelemetry in?

BioTelemetry's product category is Remote Cardiac Diagnostics and Monitoring. Its primary akta.pro industry code is HLAHACAB, Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders), with a secondary code of HLACAPAB, Connected Medical Devices & Wearables (Sensors, Patches, Implantables). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
LinkedInTop Digital Biomarker Companies & How to Compare Them (2025)Verified Market Reports published an overview of the digital biomarker market, projecting growth from USD 3.5 billion in 2024 to USD 11.2 billion by 2033 with a CAGR of 15.9%. The article evaluates key vendors including BioTelemetry, Medtronic, IBM Watson Health, and Apple based on criteria such as data accuracy, regulatory compliance, and technology integration. It highlights specific use cases for clinical trials, chronic disease management, and consumer wearables while noting trends toward AI-driven insights and market consolidation.LinkedInWearable Heart Rate Sensor Module in the Real World: 5 Uses You'll Actually See (2025)Wearable heart rate sensor modules are increasingly integrated into health tech, fitness, and clinical settings by 2025 to provide real-time data for monitoring and analysis. Key applications include personal fitness tracking, remote patient monitoring for chronic conditions, clinical research, workplace wellness programs, and athletic performance optimization. The market ecosystem includes major technology firms like Apple, Google (Fitbit), Samsung, and specialized medical device manufacturers such as Masimo and BioTelemetry.DAICiRhythm Presents New Data on Ambulatory Cardiac MonitoringiRhythm Technologies presented data from the AVALON study at the Heart Rhythm Society’s annual meeting, demonstrating that its Zio long-term continuous monitoring service achieved higher diagnostic yields and lower rates of repeat testing and cardiovascular events compared to other ambulatory cardiac monitoring modalities in a commercially insured population. The analysis of 428,707 patients reinforced the clinical superiority of the Zio system over competitors such as Bardy, BioTelemetry, and Preventice, while also highlighting improved patient engagement through the MyZio app.PR NewswirePhiladelphia-area Company To Pay $45 Million Whistleblower Settlement For Outsourcing Heart Monitoring To IndiaMalvern, Pennsylvania-based BioTelemetry, Inc., now a subsidiary of Royal Philips, has agreed to pay $44.875 million to settle allegations that it defrauded U.S. taxpayers by outsourcing remote heart monitoring services to technicians in India who were not properly trained or certified between 2013 and 2022. The settlement, arising from a whistleblower lawsuit filed in federal court in Philadelphia in 2018, found that fewer than 3 percent of technicians who reviewed data of U.S. Medicare patients were properly certified as required by federal law. The whistleblowers will receive $8.3 million from the settlement under the federal False Claims Act, which allows private citizens to report fraud against federal programs.PR NewswireTelehealth Market Exceed valuation of USD 230.33 Billion with a Potential Growth rate of 35.18% by 202, Market Analysed by Size, Shares, Trends, Growth and Revenue OutlookData Bridge Market Research published a global telehealth market report projecting the market to reach USD 230.33 billion by 2029, growing at a compound annual growth rate of 35.18% during the forecast period of 2020 to 2029. The report identifies key growth drivers including increased smartphone and connected device penetration, advancements in internet connectivity, and rising prevalence of chronic and infectious diseases. Notable recent developments cited include Philips' acquisition of BioTelemetry Inc. in February 2021 and The Dedalus Group's agreement to acquire DXC Technology's healthcare software solutions division in May 2020.PR NewswireDigital Health Monitoring Devices Market is flourishing at CAGR Of +18.87% with Size, Share, Emerging Trends, Historic Analysis and Industry Growth Factors by 2029Data Bridge Market Research published a report projecting the global digital health monitoring devices market to reach USD 15.35 billion by 2029, growing at a CAGR of 18.87% during the forecast period, driven by rising chronic diseases, telehealth adoption, and healthcare infrastructure investments. The report highlights recent strategic collaborations including Philips' partnership with BioIntelliSense in July 2020 to integrate BioSticker devices into remote patient monitoring solutions. Additionally, BioTelemetry acquired the On.Demand remote patient monitoring platform from Envolve People Care Inc., a Centene Corporation subsidiary, expanding its chronic care monitoring portfolio.MedicaldesignandoutsourcingMedtech M&A: The industry’s biggest mergers and acquisitions of 2021Royal Philips completed its $2.8 billion acquisition of BioTelemetry in February 2021, sealing a deal initially agreed upon in December 2020, with BioTelemetry becoming a wholly-owned subsidiary. BioTelemetry, with approximately 1,900 employees, develops diagnostics and monitors for heart rhythm disorders, including wearable heart monitors and AI-based data analytics. The acquisition is intended to complement Philips' in-hospital patient monitoring business with BioTelemetry's cardiac diagnostics and monitoring technologies for outside the hospital setting.PR NewswirePandemic Accelerates Adoption of Electronic Skin Patches, Reports IDTechExThe COVID-19 pandemic accelerated the adoption of electronic skin patches for remote patient monitoring, with regulatory hurdles lowered and demand surging for contactless health solutions. Philips' $2.8 billion acquisition of BioTelemetry in December 2020 was highlighted as the largest and most significant deal in this space, reflecting major medical device companies integrating skin patch technologies into digital healthcare ecosystems. The report covers over 130 companies and projects market trends from 2010 through 2031.GlobeNewswirePhilips successfully completes tender offer for BioTelemetry, Inc.Philips completed its tender offer to buy all BioTelemetry shares at $72 per share, with 78.96% of shares tendered. The merger will make BioTelemetry a wholly owned subsidiary, and its stock will be delisted from NASDAQ.PR NewswireInvestors Bancorp Set to Join S&P SmallCap 600Investors Bancorp Inc. will replace BioTelemetry Inc. in the S&P SmallCap 600 index effective prior to market open on February 10, 2021. BioTelemetry is being removed from the index because Koninklijke Philips N.V. is acquiring the company in a deal expected to close soon pending final conditions. The announcement details the addition of Investors Bancorp under the Financials GICS sector and the deletion of BioTelemetry under the Health Care sector.